Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303732 · ClinicalTrials.gov registry record · Phase 1
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00303732: Completed Phase 1 study, sponsored by Daniel George, MD.
NCT00303732 is a Phase 1 study that has completed, run by Daniel George, MD. The registered enrollment target is 37 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303732, a Phase 1 study, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in treating patients with advanced solid tumors.
Primary Outcome
Patients were evaluated on Day 1,14 and 28 for dose limiting toxicities
Interventions
- DRUG RAD001 (everolimus)
- DRUG PTK787 (vatalanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
What the finished NCT00303732 record still lists
NCT00303732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 2 interventions - of which RAD001 (everolimus) is the first listed.
NCT00303732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303732 about?
NCT00303732 is a clinical study titled "Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors". RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and everolimus and to see how well they work in ...
What is the current status of trial NCT00303732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2004-12. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00303732?
The interventions under investigation include: RAD001 (everolimus) (DRUG), PTK787 (vatalanib) (DRUG).
Who is sponsoring clinical trial NCT00303732?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303732's enrollment target sits among peer trials
37 1204th of 2000 higher than 791 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia